<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

LY 2801653 - Merestinib

產(chǎn)品貨號(hào)

Axon 2553 CAS [1206799-15-6] MF C30H22F2N6O3MW 552.53 Purity: 99% Soluble in DMSO Description Orally bioavailable multi-kinase inhibitor with potent activity against c-MET (IC50 values 35 - 53 nM for cell-based activity), and several other receptor tyrosine oncokinases including MST1R, FLT3, AXL, MERTK, TEK, ROS1, DDR1, DDR2 and against the serine/threonine kinases MKNK1 and MKNK2 (IC50 values 11, 7, 2, 10, 63, 23, 0.1, 7, 7, and 7 nM, respectively). In classic and orthotopic mouse xenograft models of lung cancer, LY2801653 decreased tumor growth, dramatically inhibiting mitotic events and angiogenesis. KEYWORDS: LY 2801653 | supplier | Multi-kinase (c-MET) inhibitor | Merestinib | LY2801653 | CAS [1206799-15-6] | HGF | c-MET | MST1R | Axl | FLT3 | MERTK | TEK | ROS1 | DDR1 | DDR2 | RTKInhibitor | MKNK1 | MKNK2 | oncoproteins

產(chǎn)品價(jià)格

現(xiàn)貨詢價(jià)，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

LY 2801653 - Merestinib

Based on 28 publications in PubMed 9 10 28

Axon 2553

CAS [1206799-15-6]

MF C30H22F2N6O3
MW 552.53

Purity: 99%
Soluble in DMSO

LY 2801653

Description

Orally bioavailable multi-kinase inhibitor with potent activity against c-MET (IC50 values 35 - 53 nM for cell-based activity), and several other receptor tyrosine oncokinases including MST1R, FLT3, AXL, MERTK, TEK, ROS1, DDR1, DDR2 and against the serine/threonine kinases MKNK1 and MKNK2 (IC50 values 11, 7, 2, 10, 63, 23, 0.1, 7, 7, and 7 nM, respectively). In classic and orthotopic mouse xenograft models of lung cancer, LY2801653 decreased tumor growth, dramatically inhibiting mitotic events and angiogenesis.

KEYWORDS: LY 2801653 | supplier | Multi-kinase (c-MET) inhibitor | Merestinib | LY2801653 | CAS [1206799-15-6] | HGF | c-MET | MST1R | Axl | FLT3 | MERTK | TEK | ROS1 | DDR1 | DDR2 | RTKInhibitor | MKNK1 | MKNK2 | oncoproteins

SB Yan et al. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Invest New Drugs. 2013 Aug;31(4):833-44.

W Wu et al. Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET. Clin Cancer Res. 2013 Oct 15;19(20):5699-710.

I. Kawada et al. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. Cancer Res. 2014 Feb 1;74(3):884-95.

Certificate of Analysis
Material Safety Data Sheet

Angiogenesis Apoptosis Cell Signaling & Oncology Stem Cell Axl c-MET FLT3 Mer RTK class X; EC 2.7.10.1 DDR1 MST1R ROS

Orally bioavailable multi-kinase inhibitor with potent activity against c-MET

Chemical name

N-(3-fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide

Parent CAS No.

[1206799-15-6]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>